Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the…
[Nile Post] Imagine a hospital in Uganda that urgently needs an oxygen plant to save patients struggling to breathe. Funds have been allocated to purchase a vehicle, but circumstances suggest that an…
Formation Bio, an AI-focused biotech that acquires outside assets, develops them and then hands them off, has raised a $600 million investment found to double down on that strategy.
